[Recent progress in the molecular-targeting treatment of neuroendocrine tumors].
Unno
Michiaki
M
Department of Surgery, Tohoku University Graduate School of Medicine, Japan. m_unno@surg1.med.tohoku.ac.jp
D000970:Antineoplastic Agents / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D016503:Drug Delivery Systems; D000068338:Everolimus; D006801:Humans; D007211:Indoles / Q000627:therapeutic use; D018358:Neuroendocrine Tumors / Q000188:drug therapy*; D015282:Octreotide / Q000627:therapeutic use; D011758:Pyrroles / Q000627:therapeutic use; D020123:Sirolimus / Q000031:analogs & derivatives / Q000627:therapeutic use; D000077210:Sunitinib
D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D007211:Indoles; D011758:Pyrroles; D000068338:Everolimus; D015282:Octreotide; D000077210:Sunitinib; D020123:Sirolimus